The Neurofibromatosis Therapeutic Acceleration Program (NTAP) was founded through a generous philanthropic gift to The Johns Hopkins University School of Medicine, allowing the NTAP to the benefit from the institution’s extensive infrastructure, dedicated neurofibromatosis clinical care center (The Johns Hopkins Comprehensive Neurofibromatosis Center), the Brain Science Institute’s NeuroTranslational Drug Discovery Program, extensive core resources, a collaborative culture, and expertise in finding innovative solutions to disease.
Although housed at Johns Hopkins, NTAP funding is not restricted to local projects. Since its inception in 2012, more than 50 investigators at 20 institutions around the world have received NTAP funding and 93% of research funding thus far has gone to investigators outside of Johns Hopkins. A major goal of NTAP is involvement of researchers from a broad range of backgrounds from around the world. Researchers with innovative approaches for treatment of plexiform and cutaneous neurofibromas are invited to submit their research proposals, regardless of their geographic location or primary field of study.